Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
1 . A compound having the structural formula
wherein each position represented as D has deuterium enrichment of no less than about 10%.
2 . The compound of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 20%.
3 . The compound of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 50%.
4 . A pharmaceutical composition comprising the compound of claim 1 together with a pharmaceutically acceptable carrier.
5 . The pharmaceutical composition of claim 4 , wherein each position represented as D in the compound has deuterium enrichment of no less than about 20%.
6 . The pharmaceutical composition of claim 4 , wherein each position represented as D in the compound has deuterium enrichment of no less than about 50%.
7 . A method of treating a hyperkinetic movement disorder in a human subject comprising administering to the subject the compound of claim 1 .
8 . The method of claim 7 , wherein each position represented as D in the compound has deuterium enrichment of no less than about 20%.
9 . The method of claim 7 , wherein each position represented as D in the compound has deuterium enrichment of no less than about 50%.
10 . The method of claim 7 , wherein the hyperkinetic movement disorder is chorea associated with Huntington's disease.
11 . The method of claim 7 , wherein the hyperkinetic movement disorder is Tardive dyskinesia.
12 . The method of claim 11 , wherein the subject is an adult human.
13 . The method of claim 8 , wherein the hyperkinetic movement disorder is chorea associated with Huntington's disease.
14 . The method of claim 8 , wherein the hyperkinetic movement disorder is Tardive dyskinesia.
15 . The method of claim 14 , wherein the subject is an adult human.
16 . The method of claim 9 , wherein the hyperkinetic movement disorder is chorea associated with Huntington's disease.
17 . The method of claim 9 , wherein the hyperkinetic movement disorder is Tardive dyskinesia.
18 . The method of claim 17 , wherein the subject is an adult human.
19 . A method of treating a hyperkinetic movement disorder in a human subject comprising administering to the subject the pharmaceutical composition of claim 4 .
20 . The method of claim 19 , wherein the hyperkinetic movement disorder is Tardive dyskinesia or chorea associated with Huntington's disease.